Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control

Tempest Therapeutics, Inc.

Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.
Confirmed ORR 17.5% (7/40) vs 10.3% (3/29) control, a 69.9% relative improvement.
47.5% (19/40) of TPST-1120 arm patients remain on treatment vs 23.3% (7/30) in control arm.
80% (32/40) in TPST-1120 arm on study vs 50% (15/30) control; safety consistent with control.
Secondary endpoints (DoR, PFS, OS) immature; full data expected at a medical meeting later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.